7/29/2023 0 Comments Andexxa![]() ![]() Andexxa generated reductions in all cost components – intubation, intensive care unit (ICU) and surgery costs – except drug costs, though drug costs were offset by the NTAP reimbursement.As a result, the analysis projected a potential total annual cost reduction of $259,608 for a hospital treating 48 of these patients per year with Andexxa in place of 4F-PCC. The total cost per hospitalization, considering new technology add-on payment (NTAP) reimbursement for eligible claims, was $49,291 for patients treated with Andexxa and $54,699 for patients treated with 4F-PCC – demonstrating a cost reduction of $5,408 with the use of Andexxa.Key findings from this analysis related to the net cost reduction Andexxa can provide for the treatment of ICH associated with oral Factor Xa inhibitors include: Food and Drug Administration (FDA) for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding – to one without it where patients were given 4-Factor Prothrombin Complex Concentrate (4F-PCC), which is only approved for the reversal of warfarin and has no impact on anti-Factor Xa levels. The analysis compared a clinical scenario with Andexxa – the first and only antidote approved by the U.S. ![]() "The findings demonstrate that healthcare providers can focus on FDA-approved indications for use, clinical evidence and society guidelines when providing care to patients rather than the cost of treatment." "This model, and the projected cost savings with Andexxa compared to 4F-PCC outlined in our study, is important to share among hospital pharmacists and administrators," said Mr.
0 Comments
Leave a Reply. |